Pre-market Movers For Oct 22 (WHR, TRV, SYMM, NFLX, NUS, FRX, LMT, MDVN, PTIE)

(RTTNews) - Gainers:

Whirlpool Corp. (WHR) is rising 5 percent to $138.26. The company's third quarter earnings surged from the previous year period and its adjusted earnings per share came above market view. The company also raised its full-year 2013 earnings forecast.

Travelers Companies, Inc. (TRV) is gaining 2 percent to $88.48. The company's third quarter profit was flat with prior year period, while its operating earnings per share topped Wall Street view. The company also announced an additional $5.0 billion of share buyback.

Symmetricom Inc. (SYMM) is surging 51 percent to $7.20 as it agreed to be acquired by Microsemi Corp. (MSCC) for $7.18 per share through a cash tender offer. Symmetricom may solicit superior proposals from third parties for a "go shop" period that extends through November 8, 2013. Microsemi expects significant synergies from this immediately accretive transaction.

Netflix Inc. (NFLX) is rising 9 percent to $388.75.

Nu Skin Enterprises Inc. (NUS) is rising 13 percent to $116.23. The company's third quarter profit more than doubled from the prior year period and topped analysts' estimate. Revenue rose 76 percent and came in above the consensus estimate. The company raised its full-year 2013 revenue guidance.

Forest Laboratories Inc. (FRX) is up 4 percent to $46.25. The company's second quarter earnings more than tripled from the year-ago quarter. Net revenues topped the consensus estimate.

Lockheed Martin Corp. (LMT) is up 3 percent to $129.06. The company's third quarter earnings improved from the prior year period and topped Street view. The company raised its full-year earnings guidance range.

Medivation, Inc. (MDVN) is up 9 percent to $54.60. The company and Astellas announced that the Phase 3 PREVAIL trial of Enzalutamide met both co-primary endpoints of overall survival and radiographic progression-free survival in chemotherapy-naive patients with advanced prostate cancer.

Pain Therapeutics Inc. (PTIE) is surging 26 percent to $4.10 based on the news that Pfizer Inc. (PFE) has informed that, having achieved technical milestones related to manufacturing, they will continue the development program for REMOXY (oxycodone) Extended-Release Capsules CII.